Table 35Results of the Univariate Sensitivity Analysis Regarding Annual Discontinuation Rate

ScenarioResult
15% for the first 2 years (base case)If λ < $118,242, glatiramer acetate is a cost-effective treatment.
If $118,242 < λ < $425,655, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $425,655 < λ < $872,972, dimethyl fumarate is a cost-effective treatment.
If λ > $872,972, natalizumab is a cost-effective treatment.
0% annual discontinuation rateIf λ < $122,032, glatiramer acetate is a cost-effective treatment.
If $122,032 < λ < $426,213, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $426,213 < λ < $880,388, dimethyl fumarate is a cost-effective treatment.
If λ > $880,388, natalizumab is a cost-effective treatment.
25% annual discontinuation rate for the first 2 yearsIf λ < $15,584, glatiramer acetate is a cost-effective treatment.
If $115,584 < λ < $425,339, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $425,339 < λ < $867,743, dimethyl fumarate is a cost-effective treatment.
If λ > $867,743, natalizumab is a cost-effective treatment.
10% annual discontinuation rate of oral treatments, 25% of injectable treatments for the first 2 yearsIf λ < $115,584, glatiramer acetate is a cost-effective treatment.
If $115,584 < λ < $416,037, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $416,037 < λ < $1,449,326, dimethyl fumarate is a cost-effective treatment.
If λ > $1,449,326, natalizumab is a cost-effective treatment.

mcg = microgram.

From: 4, RESULTS

Cover of Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis
Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis [Internet].
CADTH Therapeutic Review, No. 1.2B.
Copyright © CADTH March 2013.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.